Skip to content

Study · Non-randomized trial · n = 9 · 1990

6 results

The secretion of insulin-like growth factors I and II by explant cultures of fibroids and myometrium from women treated with a gonadotropin-releasing hormone agonist.

Rein MS, Friedman AJ, Pandian MR, Heffner LJ

Obstetrics and gynecology1 Sept 1990Cited by 38 (Europe PMC)

PMID2116610 (opens in a new tab)PepBankPUB-02116610
Publisher pageAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 1 result from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In women with fibroids, leuprolide treatment reduced uterine volume by 34%.

    In plain wordsIn women with fibroids, uterine volume decreased by 34% during leuprolide treatment.

    Peptide
    Leuprolide
    Outcome
    DecreaseUterine volume
    Study

    n = 9

    Comparator
    Pretreatment
    Outcome group
    Uterine Volume · Reproductive and sexual health
    Studied dose
    3.75 mg every 28 daysAs given in this study (human).

    Measurements

    Uterine volume reduction
    34%
    leuprolide treatment

    Source sentences

    Summary
    Patients treated with GnRH-a demonstrated a 34% reduction in uterine volume, whereas placebo-treated patients exhibited no change.
    2 context sentences
    Summary · context
    Patients were randomized to receive either leuprolide 3.75 mg every 28 days (N = 9) or placebo injections (N = 8) before myomectomy.
    Summary · context
    Fresh tissue was diced into 2-mm3 explants and cultures were established in serum-free media.
  2. 02LabEx vivo tissueMechanism

    In women treated before myomectomy, leuprolide reduced fibroid explant IGF-I secretion versus placebo.

    In plain wordsIn lab tests, fibroid samples from leuprolide recipients released less IGF-I than samples from placebo recipients.

    Peptide
    Leuprolide
    Outcome
    DecreaseFibroid explant IGF-I secretion
    Study

    humann = 17

    Fibroid explant cultures after human pretreatment
    Comparator
    Placebo
    Outcome group
    Growth hormone and IGF-1 · Reproductive and sexual health
    Studied dose
    3.75 mg every 28 daysAs given in this study (human).

    Source sentences

    Summary
    The secretion of IGF-I and IGF-II by fibroid explants obtained from women treated with the GnRH-a was significantly less than that in tissue obtained from placebo-treated controls (P less than .01 and P less than or equal to .05, respectively).
    2 context sentences
    Summary · context
    Patients were randomized to receive either leuprolide 3.75 mg every 28 days (N = 9) or placebo injections (N = 8) before myomectomy.
    Summary · context
    Fresh tissue was diced into 2-mm3 explants and cultures were established in serum-free media.
  3. 03LabEx vivo tissueMechanism

    In women treated before myomectomy, leuprolide reduced fibroid explant IGF-II secretion versus placebo.

    In plain wordsIn lab tests, fibroid samples from leuprolide recipients released less IGF-II than samples from placebo recipients.

    Peptide
    Leuprolide
    Outcome
    DecreaseFibroid explant IGF-II secretion
    Study

    humann = 17

    Fibroid explant cultures after human pretreatment
    Comparator
    Placebo
    Outcome group
    Growth hormone and IGF-1 · Reproductive and sexual health
    Studied dose
    3.75 mg every 28 daysAs given in this study (human).

    Source sentences

    Summary
    The secretion of IGF-I and IGF-II by fibroid explants obtained from women treated with the GnRH-a was significantly less than that in tissue obtained from placebo-treated controls (P less than .01 and P less than or equal to .05, respectively).
    2 context sentences
    Summary · context
    Patients were randomized to receive either leuprolide 3.75 mg every 28 days (N = 9) or placebo injections (N = 8) before myomectomy.
    Summary · context
    Fresh tissue was diced into 2-mm3 explants and cultures were established in serum-free media.
  4. 04LabEx vivo tissueMechanism

    In women treated before myomectomy, leuprolide reduced myometrial explant IGF-I secretion versus placebo.

    In plain wordsIn lab tests, uterine muscle samples from leuprolide recipients released less IGF-I than samples from placebo recipients.

    Peptide
    Leuprolide
    Outcome
    DecreaseMyometrial explant IGF-I secretion
    Study

    humann = 17

    Uterine muscle explant cultures after human pretreatment
    Comparator
    Placebo
    Outcome group
    Growth hormone and IGF-1 · Reproductive and sexual health
    Studied dose
    3.75 mg every 28 daysAs given in this study (human).

    Source sentences

    Summary
    Similarly, the secretion of IGF-I and IGF-II by myometrial explants was significantly less in tissue obtained from women treated with GnRH-a (P less than .0001 for both IGF-I and IGF-II).
    3 context sentences
    Summary · context
    The secretion of IGF-I and IGF-II by explant cultures of fibroids and myometria from women treated with a GnRH-a was compared with that of tissue obtained from placebo-treated controls.
    Summary · context
    Patients were randomized to receive either leuprolide 3.75 mg every 28 days (N = 9) or placebo injections (N = 8) before myomectomy.
    Summary · context
    Fresh tissue was diced into 2-mm3 explants and cultures were established in serum-free media.
  5. 05LabEx vivo tissueMechanism

    In women treated before myomectomy, leuprolide reduced myometrial explant IGF-II secretion versus placebo.

    In plain wordsIn lab tests, uterine muscle samples from leuprolide recipients released less IGF-II than samples from placebo recipients.

    Peptide
    Leuprolide
    Outcome
    DecreaseMyometrial explant IGF-II secretion
    Study

    humann = 17

    Uterine muscle explant cultures after human pretreatment
    Comparator
    Placebo
    Outcome group
    Growth hormone and IGF-1 · Reproductive and sexual health
    Studied dose
    3.75 mg every 28 daysAs given in this study (human).

    Source sentences

    Summary
    Similarly, the secretion of IGF-I and IGF-II by myometrial explants was significantly less in tissue obtained from women treated with GnRH-a (P less than .0001 for both IGF-I and IGF-II).
    3 context sentences
    Summary · context
    The secretion of IGF-I and IGF-II by explant cultures of fibroids and myometria from women treated with a GnRH-a was compared with that of tissue obtained from placebo-treated controls.
    Summary · context
    Patients were randomized to receive either leuprolide 3.75 mg every 28 days (N = 9) or placebo injections (N = 8) before myomectomy.
    Summary · context
    Fresh tissue was diced into 2-mm3 explants and cultures were established in serum-free media.
  6. 06LabEx vivo tissueMechanism

    In treated women, fibroid protein secretion did not differ significantly between leuprolide and placebo.

    In plain wordsIn lab tests, fibroid samples from leuprolide and placebo recipients did not differ significantly in protein release.

    Peptide
    Leuprolide
    Outcome
    No significant changeFibroid protein secretion
    Study

    humann = 17

    Fibroid explant cultures after human pretreatment
    Comparator
    Placebo
    Outcome group
    Protein Secretion · Reproductive and sexual health
    Studied dose
    3.75 mg every 28 daysAs given in this study (human).

    Source sentences

    Summary
    Protein secretion by fibroid tissue obtained from women treated with GnRH-a was not significantly different when compared with tissue from placebo-treated controls.
    2 context sentences
    Summary · context
    Patients were randomized to receive either leuprolide 3.75 mg every 28 days (N = 9) or placebo injections (N = 8) before myomectomy.
    Summary · context
    Fresh tissue was diced into 2-mm3 explants and cultures were established in serum-free media.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:37 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.